文献速递肝病

慢性丙型肝炎患者抗病毒治疗后肝脏硬度下降的幅度与动力学:系统综述与荟萃分析

Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-05-04

该系统综述与荟萃分析纳入24项观察性研究或随机对照试验,评估慢性丙型肝炎患者抗病毒治疗后肝脏硬度变化。获得持续病毒学应答(SVR)者肝脏硬度显著下降,且随时间延长降幅增大;未获得SVR者无显著变化。直接抗病毒药物、基线肝硬化及高丙氨酸氨基转移酶水平者下降更显著。

要点

  • 获得SVR者肝脏硬度中位下降28.2%(四分位距21.8-34.8)。
  • 未获得SVR者6-12个月肝脏硬度下降0.6 kPa(95%CI -1.7至0.5),无显著变化。
  • 基线肝脏硬度>9.5 kPa者中47%(95%CI 27%-68%)治疗后降至<9.5 kPa。

核心结论

  • 根除丙型肝炎病毒感染(获得SVR)与肝脏硬度显著下降相关,尤其在基线炎症水平高或接受直接抗病毒药物治疗的患者中。
  • 基于VCTE判断为晚期纤维化的患者中,近半数治疗后肝脏硬度降至<9.5 kPa。

研究设计与样本

  • 系统综述与荟萃分析,检索截至2016年10月的文献,纳入24项观察性研究或随机对照试验。
  • 研究对象为接受抗病毒治疗(直接抗病毒药物或干扰素为基础方案)且治疗前及治疗后至少1次VCTE的成人丙型肝炎病毒感染者。
  • 采用随机效应荟萃分析估计获得与未获得SVR患者肝脏硬度加权均数差及95%置信区间。

主要发现

  • 获得SVR者肝脏硬度在治疗结束时下降2.4 kPa(95%CI -1.7至-3.0),治疗后1-6个月下降3.1 kPa(95%CI -1.6至-4.7),6-12个月下降3.2 kPa(90%CI -2.6至-3.9),12个月及以上下降4.1 kPa(95%CI -3.3至-4.9),中位下降28.2%(四分位距21.8-34.8)。
  • 未获得SVR者6-12个月肝脏硬度下降0.6 kPa(95%CI -1.7至0.5),无显著变化。
  • 直接抗病毒药物治疗者肝脏硬度下降4.5 kPa,干扰素为基础治疗者下降2.6 kPa(P = .03)。
  • 基线肝硬化者肝脏硬度下降5.1 kPa,无肝硬化者下降2.8 kPa(P = .02)。
  • 基线丙氨酸氨基转移酶高水平者肝脏硬度下降更显著(P < .01)。

关键数值与推荐

  • 基线肝脏硬度>9.5 kPa者中47%(95%CI 27%-68%)治疗后肝脏硬度<9.5 kPa。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We performed a systematic review and meta-analysis to estimate the decrease in liver stiffness, measured by vibration-controlled transient elastrography (VCTE), in patients with hepatitis C virus infection who achieved a sustained virologic response (SVR). METHODS: We searched the literature through October 2016 for observational studies or randomized controlled trials of adults with hepatitis C virus infection who received antiviral therapy (either direct-acting antiviral agents or interferon-based therapies), underwent liver stiffness measurement using VCTE before starting therapy, and had at least 1 follow-up VCTE after completion of therapy; studies also provided data on mean or median liver stiffness measurements for patients who did and did not achieve an SVR. We identified 24 studies, and estimated weighted mean difference (and 95% confidence interval) in liver stiffness in patients with versus without SVR using random-effects meta-analysis. RESULTS: In patients who achieved SVR, liver stiffness decreased by 2.4 kPa at the end of therapy (95% CI, -1.7 to -3.0), by 3.1 kPa 1-6 months after therapy (95% CI, -1.6 to -4.7), by 3.2 kPa 6-12 months after therapy (90% CI, -2.6 to -3.9), and 4.1 kPa 12 months or more after therapy (95% CI, -3.3 to -4.9) (median decrease, 28.2%; interquartile range, 21.8-34.8). In contrast, there was no significant change in liver stiffness in patients who did not achieve an SVR (at 6-12 months after therapy, decrease of 0.6 kPa; 95% CI, -1.7 to 0.5). Decreases in liver stiffness were significantly greater in patients treated with direct-acting antiviral agents than with interferon-based therapy (decrease of 4.5 kPa vs decrease of 2.6 kPa; P = .03), cirrhosis at baseline (decrease of 5.1 kPa vs decrease of 2.8 kPa in patients with no cirrhosis; P = .02), or high pretreatment levels of alanine aminotransferase (P < .01). Among patients with baseline liver stiffness >9.5 kPa, 47% (95% CI, 27%-68%) achieved posttreatment liver stiffness of <9.5 kPa. CONCLUSIONS: In a systematic review and meta-analysis, we associated eradication of hepatitis C virus infection (SVR) with significant decreases in liver stiffness, particularly in patients with high baseline level of inflammation or patients who received direct-acting antiviral agents. Almost half the patients considered to have advanced fibrosis, based on VCTE, before therapy achieved posttreatment liver stiffness levels <9.5 kPa. Clinical Trial Registration no: CRD42016051034.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singh S, Facciorusso A, Loomba R, et al. Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017. PMID: 28479504. doi:10.1016/j.cgh.2017.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。